– Congenital Heart Defects Program Sets Foundation for Exponential Market Expansion
As %Healthcare systems globally demand more cost-effective diagnostic solutions, %AI enhanced %Echocardiography represents the convergence of advanced technology with practical accessibility.
VentriPoint’s approach addresses this market need through a recently-announced focus on major underserved patient populations.
VentriPoint Diagnostics has announced a targeted marketing program focused on congenital heart defects. This not only brings an efficient and cost-effective solution to a set of users worldwide that require lifelong monitoring, but also sets the stage for expansion into cardio-oncology, pulmonary hypertension, heart failure, and valvular disease diagnostics markets.
VPT & CHD: Tackling The Hardest Challenges
%VentriPoint Diagnostics (TSXV: $VPT) (OTC: $VPTDF) has unveiled a full-stack marketing program targeting congenital heart defects (CHD), a strategic move designed to establish market leadership in one of cardiac imaging’s most challenging segments by doing away with major access hurdles, while creating the foundation for rapid expansion into multiple high-value therapeutic areas.
The initiative leverages VentriPoint’s core competitive advantage: delivering MRI-comparable cardiac analysis through standard echocardiography equipment. For CHD patients who require lifelong cardiac monitoring but often face accessibility barriers to MRI imaging, the company’s VMS+ technology addresses a critical unmet need.
“CHD patients face a lifetime of imaging, yet many cannot access MRI due to cost, availability, or clinical limitations. Our VMS+ technology solves that challenge by enabling fast, accurate, and comfortable assessments using widely available ultrasound equipment. By leading in CHD, we are also building the clinical credibility and installed base needed to accelerate adoption in other high-value segments.”
Hugh MacNaught, President and CEO
The Program
VentriPoint’s CHD initiative operates through a four-pillar marketing strategy combining industry partnerships with ASCEND Cardiovascular, expanded relationships with pediatric and adult congenital cardiology centers, patient advocacy through CHD organizations, and key opinion leaders publishing case studies and peer-reviewed data reinforcing VMS+ as standard of care.
CHD represents the most challenging patient population for %CardiacImaging. Proven value there validates the technology across several major cardiac conditions while building essential clinical credibility.
A Well-Structured Roll-Out
The CHD program serves as VentriPoint’s on-ramp into other rapidly growing cardiac segments where fast, non-invasive volumetric analysis creates significant clinical and economic value. The company has identified four primary expansion targets representing substantial market fits.
– Cardio-oncology: involves monitoring heart damage in cancer patients undergoing potentially cardiotoxic treatments.
– Pulmonary hypertension: requires tracking right heart changes and therapeutic response in complex pulmonary conditions.
– Heart failure management: demands assessing cardiac performance and monitoring therapeutic interventions.
– Valvular heart disease: focuses on evaluating suitability for valve procedures and monitoring post-intervention outcomes.
Pulling The Right Levers
The multi-segment strategy significantly expands VentriPoint’s addressable market while leveraging existing clinical relationships and regulatory approvals. Success in CHD validates the technology’s capabilities across the most demanding applications, creating natural expansion opportunities into related cardiac specialties.
Under seasoned leadership with three decades of medical technology commercialization experience, VentriPoint’s approach to market expansion follows proven pathways for building clinical adoption and commercial traction. The CHD foundation provides the clinical credibility and installed base necessary for accelerated growth across multiple high-value segments.
“Each of these markets represents a significant growth opportunity, but CHD offers a unique platform for proving our value proposition in the most challenging and underserved patient population. From there, our addressable market expands exponentially.”
– Hugh MacNaught
Making a Statement
VentriPoint’s strategic CHD initiative demonstrates the company’s systematic approach to market expansion while addressing multiple billion-dollar therapeutic segments. The program’s comprehensive architecture spans through industry partnerships, clinical education, advocacy engagement, and thought leadership, while also creating multiple pathways for accelerated adoption.
By establishing leadership in the most challenging cardiac imaging applications, VentriPoint builds the foundation for sustained growth across rapidly expanding medical specialties where accessible, accurate cardiac assessment drives clinical and economic value.
About VentriPoint
Ventripoint (TSXV: VPT; OTCQB: VPTDF) is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+ products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
Disclaimer: This article is for informational purposes only and does not constitute a solicitation or offer. The accuracy of the information is not guaranteed. Consult with your financial advisor before making any decisions relating to Ventripoint Diagnostics Ltd. or any other company named herein. Unauthorized use, disclosure or distribution of this article is prohibited. Ventripoint Diagnostics Ltd. is not liable for errors or omissions in this article. This article is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Castle Rising assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Yolowire has been compensated eight hundred dollars by Castle Rising for distribution of this Ventripoint Diagnostics Ltd. press release. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Yolowire was not compensated by any public company mentioned herein to disseminate this press release.
